Danaher Corporation DHR NYSE

Danaher Corporation (DHR) reported total assets of $83.46B and total liabilities of $30.93B for fiscal year 2025, resulting in total equity of $52.54B.

The company held $4.62B in cash and short-term investments. Total debt stood at $18.42B, with net debt of $13.8B. The Debt-to-Equity (D/E) ratio was 0.35 (conservative).

Current ratio is 1.87, indicating strong short-term liquidity. Interest coverage is 19.4x (strong).

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.35, current ratio of 1.87, interest coverage 19.4x — balance sheet is strong
• MOAT (86/100) — Total assets $83.46B and equity $52.54B support the company's competitive scale
• VALUE (32/100) — Debt-to-Equity 0.35 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 67/100 with 4/7 criteria passed.

TMO

Thermo Fisher Scientific Inc.

$527.22

+2.53%

AMGN

Amgen Inc.

$350.95

+0.32%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%

ISRG

Intuitive Surgical, Inc.

$467.22

+1.80%

PFE

Pfizer Inc.

$27.13

-0.77%

SYK

Stryker Corporation

$345.88

-0.39%

SNY

Sanofi

$47.64

+1.45%

MDT

Medtronic plc

$88.12

+0.14%